NINLARO is licensed in combination with lenalidomide and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.
This website has been developed by Takeda Oncology and contains product and prescribing information intended for UK healthcare professionals. In addition, the site contains specific information for patients prescribed NINLARO. General information on multiple myeloma for the general public is also included.
The link you have selected is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.
Please confirm you wish to follow this link.